{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-051944","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.561592+00:00","generated_at":"2026-06-03T07:49:54.815178+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Immunome appoints Dr. Sandra Swain as Class III director, joins Audit Committee","bullets":["Appointment effective April 25, 2024; term expires at 2026 annual meeting.","Annual cash retainer: $40,000 for Board, $7,500 for Audit Committee membership.","Initial option grant of $270,000 Black-Scholes value, vesting quarterly over three years.","Isaac Barchas stepped down from Audit Committee; new members: Schafer (Chair), Swain, Bienaimé.","Dr. Swain also receives automatic annual option grants of $135,000 vesting over 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-051944","json":"https://secwatch.observer/filing/0001104659-24-051944.json","markdown":"https://secwatch.observer/filing/0001104659-24-051944.md","text":"https://secwatch.observer/filing/0001104659-24-051944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924051944/0001104659-24-051944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924051944/tm2412702d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:49:54.815178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06cf515a11","claim":"Sandra Swain was appointed as Class III Director at Immunome Inc..","evidence_excerpt":"appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924051944/0001104659-24-051944-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}